LENZ Therapeutics, Inc. expected to post a loss of 91 cents a share - Earnings Preview
LENZ Therapeutics, Inc. LENZ.O is expected to show a fall in quarterly revenue when it reports results on October 29 for the period ending September 30 2026
The Solana Beach California-based company is expected to report a 66.4% decrease in revenue to $4.2 million from $12.5 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
LSEG's mean analyst estimate for LENZ Therapeutics, Inc. is for a loss of 91 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for LENZ Therapeutics, Inc. is $10.00, about 218% above its last closing price of $3.15
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2026 | -1.20 | -1.07 | -1.02 | Beat | 5.1 |
Mar. 31 2026 | -1.09 | -1.07 | -1.32 | Missed | -23.5 |
Dec. 31 2025 | -0.86 | -0.97 | -1.16 | Missed | -19.4 |
Sep. 30 2025 | -0.67 | -0.71 | -0.59 | Beat | 16.5 |
Jun. 30 2025 | -0.63 | -0.61 | -0.51 | Beat | 16.4 |
Mar. 31 2025 | -0.54 | -0.55 | -0.53 | Beat | 4.2 |
Dec. 31 2024 | -0.41 | -0.46 | Missed | -11.3 | |
Sep. 30 2024 | -0.46 | -0.46 | -0.38 | Beat | 18.2 |
This summary was machine generated October 27 at 11:35 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)